Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU

Category Primary study
Year 1999
This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The use of irinotecan (IRI) as second-line therapy for metastatic colorectal cancer was cost-effective in comparison with standard 5-fluorouracil (5-FU).
Epistemonikos ID: bb716c329bb2596c2c068ea9fa1c18b44ece876e
First added on: Apr 19, 2023